Clinical trials: Gynecological Tumors
Ovarian Neoplasms
Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.
ANGLE has developed the Parsortix™ Cell Separation System (Parsortix), an automated system capable of harvesting rare circulating cells for analysis from a sample of peripheral blood based on cellular size and deformability.
- Trial name
- NCT02785731
- Testing
- Pelvic imaging, Blood draw, laparotomy or laparoscopy
- Where
- 5 sites in Austria, Germany
- Volunteers
- 204 people
- Sponsor
- Angle plc
Gynecologic Cancer, Cancer Metastatic
Study of AK112 in the Treatment of Advanced Gynecological Tumors
A phase II study to evaluate the efficacy and safety of AK112 in subjects with advanced gynecological tumors.
- Conditions
- Gynecologic Cancer, Cancer Metastatic, Ovarian Neoplasms, Cervical Neoplasm
- Trial name
- NCT04870177
- Testing
- AK112
- Where
- 2 sites in China
- Volunteers
- 53 people
- Sponsor
- Akeso
Advanced Gynecological Cancers, Ovarian Cancer
A Trial of Atezolizumab and Vigil in Patients With Advanced Gynecological Cancers
The clinical trial was a companion study to protocol CL-PTL-119 (A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects with Stage IIIb-IV Ovarian Cancer…
- Conditions
- Advanced Gynecological Cancers, Ovarian Cancer, Cervical Cancer, Uterine Cancer
- Trial name
- NCT03073525
- Testing
- Vigil, Atezolizumab
- Where
- 6 sites in United States
- Volunteers
- 25 people
- Sponsor
- Gradalis, Inc.
Gynecological Tumors, Solid Tumors
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid Tumors
This study is an open-label, multicenter, dose-escalation and expansion, non-randomized Phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of SI-B036 bispecific…
- Trial name
- NCT07778862
- Testing
- SI-B036
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Renal Cell Carcinoma, Urothelial Carcinoma
Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors
Phase II multi-chort, adaptive two-stage, open label, nonrandomized study. The aim of our study is to evaluate the efficacy and safety of anti-PD-1 antibody SHR-1210(Camrelizumab) in combination with a small-molecule multikinase…
- Conditions
- Renal Cell Carcinoma, Urothelial Carcinoma, Cervical Cancer, Ovarian Cancer Recurrent
- Trial name
- NCT03827837
- Testing
- SHR-1210, Famitinib
- Where
- China
- Volunteers
- 265 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Gynecological Tumors
A Clinical Trial of TQB2102 for Injection in Gynecological Tumors With Recurrent/Metastatic Advanced
TQB2102 is an antibody-drug conjugate comprised of a humanised antibody against Human Epidermal Growth Factor Receptor 2 (HER2), a enzyme-cleavable linker, and a topoisomerase I inhibitor payload, which combine the ability of…
- Trial name
- NCT06798207
- Testing
- TQB2102 for injection
- Where
- 31 sites in China
- Volunteers
- 170 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Tumours, Gynecological
A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2)
Advanced solid tumors are cancers that have spread to other parts of the body. While many treatments exist, most people become resistant to them, and the cancer returns.
- Trial name
- NCT06796907
- Testing
- Mo-Rez, Dostarlimab, Bevacizumab
- Where
- 83 sites in United States, Argentina and 21 more
- Volunteers
- 305 people
- Sponsor
- GlaxoSmithKline
Cervical Cancer, Ovarian Cancer
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or…
- Trial name
- NCT06769152
- Testing
- HLX43
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Shanghai Henlius Biotech
Gynaecological Cancers
GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort
Adult patients with gynecologic cancer (endometrial, ovarian, cervical, vulvar and vaginal cancers) treated at Oncoclínicas \& CO sites will be enrolled for primary tumor immunohistochemistry (IHC) analysis.
- Trial name
- GYNGHER (NCT07101081)
- Testing
- HER-2 Test
- Where
- Brazil
- Volunteers
- 350 people
- Sponsor
- AstraZeneca
Ovarian Cancer, Fallopian Tube Cancer
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
- Trial name
- NCT06906341
- Testing
- Relacorilant 150 mg once daily (QD), Nab-paclitaxel 80 mg/m^2, Bevacizumab 10 mg/kg
- Where
- 49 sites in United States, Belgium and 6 more
- Volunteers
- 270 people
- Sponsor
- Corcept Therapeutics
Ovarian Cancer
A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable
This randomized, open-label study will evaluate the efficacy and safety of neoadjuvant bevacizumab in participants with initially unresectable, FIGO stage IIIC/IV ovarian, tubal, or peritoneal cancer.
- Trial name
- ANTHALYA (NCT01739218)
- Testing
- Carboplatin, Paclitaxel, Bevacizumab
- Where
- 15 sites in France
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
Ovarian Cancer, Endometrial Cancer
Biomarkers for Gynecologic Cancer
A novel blood metabolic biomarker, AminoIndexTM (gynecological), was developed for gynecological cancers from over 400 Japanese patient's plasma free amino acid profiles (PFAAs) by a rapid and sensitive LC-MS (Liquid…
- Conditions
- Ovarian Cancer, Endometrial Cancer, Benign Gynecological Disease
- Trial name
- NCT02178462
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Ajinomoto Co., Inc.
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Solid Tumor, Gynecological Tumors
Clinical Study of Autologous Tumor Infiltrating Lymphocyte Injection (GT316) in the Treatment of Advanced Solid Tumors (Gynecological Tumors)
This study is a single-arm, open clinical trial.This trial consists of two phases, dose-escalation and expansion, and the study process is divided into: a screening period, a sampling and production period, a NMA-LD chemotherapy…
- Trial name
- NCT06145802
- Testing
- GT316
- Sponsor
- Grit Biotechnology
Neoplasm, Gynecologic
First In Human Safety, Pharmacokinetics and Anti-tumoral Activity of GM102 in Gynecological Cancers
First in Human study, assessing the safety profile, the pharmacokinetics and preliminary antitumor activity of GM102, a new compound (a monoclonal antibody), in patients with previously treated gynecological cancers bearing the…
- Trial name
- NCT02978755
- Testing
- GM102, GM102 escalating doses
- Where
- 12 sites in Belgium, France and 1 more
- Volunteers
- 78 people
- Sponsor
- GamaMabs Pharma
Solid Tumors
Study of INCB123667 in Subjects With Advanced Solid Tumors
This is an open-label, dose-escalation and dose-expansion study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCB123667 when administered as monotherapy and in combination with…
- Trial name
- NCT05238922
- Testing
- INCB0123667, Palbociclib, Bevacizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 291 people
- Sponsor
- Incyte Corporation
Ovarian Cancer, Epithelial Ovarian Cancer
ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
The purpose of this study is to determine how patients with ovarian, fallopian tube, and primary peritoneal cancer will best respond to treatment with rucaparib versus chemotherapy.
- Conditions
- Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT02855944
- Testing
- Chemotherapy, Rucaparib
- Where
- 77 sites in United States, Brazil and 10 more
- Volunteers
- 349 people
- Sponsor
- pharmaand GmbH
Gynecological Malignancies
9MW2821 Combined With Other Antitumor Drugs in Patients With Advanced Gynecological Tumors
To evaluate the safety, tolerability, and preliminary efficacy of 9MW2821 in combination with other anti-tumor agents in patients with advanced gynecological malignancies.
- Trial name
- NCT06926998
- Testing
- 9MW2821+other anticancer therapy
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Ovarian Cancer, Cervical Cancer
Sirius in Gynaecological Laparoscopic Surgery
Precision Robotics' Sirius Robotic Flexible Endoscopic System is a new fully integrated compact 3D laparoscopic camera system with a disposable single-use flexible tip that can change its viewing direction.
- Conditions
- Ovarian Cancer, Cervical Cancer, Gynecologic Cancer
- Trial name
- NCT05048407
- Testing
- Gynaecological laparoscopic surgery (Sirius System)
- Where
- Hong Kong
- Volunteers
- 30 people
- Sponsor
- Precision Robotics (Hong Kong) Limited